Showing 501-510 of 4136 results for "".
Derms Fight MOC; Cipher Buys Innocutis
https://practicaldermatology.com/topics/practice-management/dermwiretv-derms-fight-moc-cipher-buys-innocutis/18930/The AAD asks the American Board of Dermatology for changes to Maintenance of Certification (MOC) requirements; Jeanine Downie, MD and Heidi Waldorf, MD discuss problems with current and proposed requirements. Galderma presents data to support new investigational adapalene 0.3%/benzoyl peroxide 2.5%Ask an Expert: What is the Role of Dermatology Hospitalists?
https://practicaldermatology.com/topics/general-topics/ask-an-expert-april-2019/19599/Helena Pasieka, MD, MS talks to host Adam Friedman, MD about the important role dermatologists can play in supporting patient care in the hospital setting. Consulting dermatologists in the hospital setting change the diagnosis up to 50% of the time!What's the Best Approach to Lichen Planus?
https://practicaldermatology.com/topics/general-topics/what-s-the-best-approach-to-lichen-planus/18286/Lichen planus doesn't garner much attention in therapeutic discussions, perhaps because it is so challenging to treat. Kevin Wang, MD, PhD talks to host Adam Friedman, MD about the challenges of managing the disease and his approach to patient care.Update on Pediatric Vulvar Lichen Sclerosis
https://practicaldermatology.com/topics/general-topics/update-on-pediatric-vulvar-lichen-sclerosis/18733/Pediatric vulvar lichen sclerosis may be under-recognized. Pediatric dermatologist Kalyan Marathe, MD talks to host Adam Friedman, MD about the importance of identifying and treating the condition, providing relief to patients and potentially avoiding unnecessary testing.Vehicle Innovations: Experts Discuss What's New
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vehicle-innovations-experts-discuss-what-s-new/18915/Peter Lio, MD and Elaine Siegfried, MD discuss recent innovations in the science behind new vehicles and how these innovations improve treatment, as well as what may hinder some patients' access to these new vehicles. They also offer tips on treatment action plans for atopic patients.DermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: AAD VMX Highlights, Upneeq Launches for Ptosis
https://practicaldermatology.com/topics/practice-management/dermwiretv-aad-vmx-highlights-upneeq-launches-for-ptosis/19931/The American Academy of Dermatology's VMX format delivers updates on a range of hot topics in dermatology, including an update on the COVID-19 dermatology vaccine registry from Esther Freeman, MD and teledermatology from Jules Lipoff, MD. Upneeq, a newly launched oxymetazoline eyedrop from RVL pharmDr. DiAnne Davis on Mentorship, Lasers, Skin of Color, and More
https://practicaldermatology.com/issues/september-2025/dr-dianne-davis-on-mentorship-lasers-skin-of-color-and-more/37643/In a recent YoungMD Connect virtual mentorship session, DiAnne Davis, MD, FAAD, a dermatologist based in Dallas, discussed her journey from patient to dermatologist, the influence of mentorship, and her commitment to advancing safe, effective cosmetic procedures for patients with skin of color.Skin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)